European Medical Technology & Services: Weekly US generic IV and biosimilar market tracker (ending June 19)

Research evidence excerpt

European Medical Technology & Services: Weekly US generic IV and biosimilar market tracker (ending June 19)

Equity Research

30 June 2026

European Medical Technology & Services

Weekly US generic IV and

biosimilar market tracker (ending

European Medical Technology & ServicesJune 19)

POSITIVE

US market trends so far in Q2 remain broadly in line with Q1, European Medical Technology &

Servicessupported by resilient IV generics and strength in biosimilars.

Kabi continues to outperform led by biosimilars momentum, Hassan+44 (0)20Al-Wakeel,7773 3898 CFA

with our US tracking suggesting modest upside risk to hassan.al-wakeel@barclays.com

Barclays, UK

forecasts, albeit against tougher comps towards the end of

Jonathon Unwin

Q2. +44 (0)20 7773 0354

jonathon.unwin@barclays.com

We update our tracking of the US generic IV & biosimilar markets for the week ending 19 June.

For the overall US market1 , sales grew c.7% y/y in the week ended 19 June, moderating vs. Rohit Rajan

+91 (0) 22 6175 1698c.42% in the prior week. IV generics growth remained resilient at c.+4% y/y, broadly in line with

rohit.rajan@barclays.com

the prior week, with Q2-to-date growth at c.+6% vs. c.+8% in Q1 26. Biosimilars growth Barclays, UK

decelerated to c.+10% y/y vs. c.+79% in the prior week, reflecting a tougher comparative base,

with Q2-to-date growth at c.+42% broadly in line with c.+39% in Q1 26. Overall, Q2 trends to Marco Pires-Cox

+44 (0)20 3134 3421date for the market remain broadly consistent with Q1 26 at +23%.

marco.pirescox@barclays.com

Barclays, UKFresenius Kabi

European Pharmaceuticals,

• IV Generics: Kabi IV generics growth remained strong at c.+11% y/y, accelerating vs. c.+8% in Biotechnology & Life Sciences

the prior week and continuing to outpace the overall IV generics market.